


L1 STRUCTURE UPLOADED

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



L2 0 S L1 SSS SAM

L3 9 S L1 SSS FULL

E OLANZAPINE/CN

SET EXPAND CONTINUOUS

L4 1 S E3

L4 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2010 ACS on STN

RN 132539-06-1 REGISTRY

ED Entered STN: 08 Mar 1991

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(CA INDEX NAME)

OTHER NAMES:

CN Integrol

CN Lanzac

CN LY 170053

CN Olanzapine

CN Oleanz

CN Olenz

CN Olimelt

CN Oliza

CN Olital

CN Zyprexa

DR 1034315-19-9

MF C17 H20 N4 S

CI COM

SR US Adopted Names Council (USAN)

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO,


CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU,

DRUGU, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSPRODUCT, IMSRESEARCH, IPA,

MEDLINE, MRCK*, PATDPASPC, PIRA, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE,

TOXCENTER, USAN, USPAT2, USPATFULL

(*File contains numerically searchable property data)



FILE 'HCAPLUS' ENTERED AT 16:42:24 ON 25 MAR 2010
L5 2 S L3 AND L4

L5 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2010 ACS on STN

TI New psychiatric drug formulation with an antipsychotic or
antidepressant
and an histamine H3 receptor antagonist for the prevention of
psychotropic
adverse effects

AB The invention relates to a drug formulation with an antipsychotic
or an antidepressant, which causes adverse effects like body
weight gain or sedation when administered, and an histamine H3
receptor antagonist or inverse agonist. The histamine H3 receptor
antagonist or inverse agonist should be present in the formulation
in therapeutically effective quantities to ensure at least one of
the three following effects on the adverse effects induced by the
antipsychotic or the antidepressant: suppression or limitation of
weight gain, suppression or limitation of the decrease in
vigilance, enhancement of the pro-cognitive effect of the
treatment.

ACCESSION NUMBER: 2005:589 HCAPLUS Full-text

DOCUMENT NUMBER: 142:79960

TITLE: New psychiatric drug formulation with an
antipsychotic

or antidepressant and an histamine H3 receptor
antagonist for the prevention of psychotropic

adverse

effects

INVENTOR(S): Schwartz, Jean Charles; Rousseau Lecomte,

Jeanne Marie

PATENT ASSIGNEE(S): Bioprojet, Fr.

SOURCE: Fr. Demande, 32 pp.

CODEN: FRXXBL

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	----

 FR 2856596 A1 20041231 FR 2003-7836
 20030627
 FR 2856596 B1 20070427
 CA 2530381 A1 20050106 CA 2004-2530381
 20040625
 WO 2005000315 A1 20050106 WO 2004-FR1628
 20040625
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,
 CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
 GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
 KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
 NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
 SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
 ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
 ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ,
 DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT,
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
 MR, NE, SN, TD, TG
 EP 1641461 A1 20060405 EP 2004-767475
 20040625
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,
 MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
 JP 2007516160 T 20070621 JP 2006-516331
 20040625
 MX 2005013877 A 20060313 MX 2005-13877
 20051216
 US 20060210624 A1 20060921 US 2005-562396
 20051227
 PRIORITY APPLN. INFO.: FR 2003-7836 A
 20030627 WO 2004-FR1628 W
 20040625
 ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 142:79960
 IC ICM A61K031-4453
 ICS A61K031-4164; A61P025-24; A61P025-18; A61K031-5513; A61K031-
 517;
 A61K031-554; A61K031-496
 CC 63-6 (Pharmaceuticals)
 IT 5786-21-0, Clozapine 85650-52-8, Mirtazapine 106266-06-2,
 Risperidone
 111974-69-7 132539-06-1, Olanzapine
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological
 activity); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)

(as antipsychotic or antidepressant; new psychiatric drug
 formulation
 with an antipsychotic or antidepressant and an histamine H3
 receptor
 antagonist for prevention of psychotropic adverse effects)
 IT 288-32-4D, Imidazole, derivative 362665-56-3,
 3-(4-Chlorophenyl)propyl 3-piperidinopropyl ether
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (as histamine H3 receptor antagonist; new psychiatric drug
 formulation
 with an antipsychotic or antidepressant and an histamine H3
 receptor
 antagonist for prevention of psychotropic adverse effects)

L6 3128 S L4
 L7 10 S L6 AND HISTAMINE H3 RECEPTORS/IT
 L8 2 S L7 AND (PY<=2003 OR AY<=2003 OR PRY<=2003)

L8 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2010 ACS on STN
 TI New psychiatric drug formulation with an antipsychotic or
 antidepressant
 and an histamine H3 receptor antagonist for the prevention of
 psychotropic

adverse effects
 AB The invention relates to a drug formulation with an antipsychotic
 or an antidepressant, which causes adverse effects like body
 weight gain or sedation when administered, and an histamine H3
 receptor antagonist or inverse agonist. The histamine H3 receptor
 antagonist or inverse agonist should be present in the formulation
 in therapeutically effective quantities to ensure at least one of
 the three following effects on the adverse effects induced by the
 antipsychotic or the antidepressant: suppression or limitation of
 weight gain, suppression or limitation of the decrease in
 vigilance, enhancement of the pro-cognitive effect of the
 treatment.

ACCESSION NUMBER: 2005:589 HCAPLUS Full-text
 DOCUMENT NUMBER: 142:79960
 TITLE: New psychiatric drug formulation with an
 antipsychotic
 or antidepressant and an histamine H3 receptor
 antagonist for the prevention of psychotropic
 adverse

effects
 INVENTOR(S): Schwartz, Jean Charles; Rousseau Lecomte,
 Jeanne Marie
 PATENT ASSIGNEE(S): Bioprojet, Fr.
 SOURCE: Fr. Demande, 32 pp.
 CODEN: FRXXBL
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	----

```

-----
FR 2856596 A1 20041231 FR 2003-7836
20030627 <--
FR 2856596 B1 20070427
CA 2530381 A1 20050106 CA 2004-2530381
20040625 <--
WO 2005000315 A1 20050106 WO 2004-FR1628
20040625 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,
CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ,
DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT,
RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE,
SN, TD, TG
EP 1641461 A1 20060405 EP 2004-767475
20040625 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,
MC, PT,
IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
JP 2007516160 T 20070621 JP 2006-516331
20040625 <--
MX 2005013877 A 20060313 MX 2005-13877
20051216 <--
US 20060210624 A1 20060921 US 2005-562396
20051227 <--
PRIORITY APPLN. INFO.: FR 2003-7836 A
20030627 <--
WO 2004-FR1628 W
20040625
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 142:79960
IC ICM A61K031-4453
ICS A61K031-4164; A61P025-24; A61P025-18; A61K031-5513; A61K031-
517;
A61K031-554; A61K031-496
CC 63-6 (Pharmaceuticals)
IT Histamine H3 receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(new psychiatric drug formulation with an antipsychotic or
antidepressant and an histamine H3 receptor antagonist for
prevention
of psychotropic adverse effects)

```

IT 5786-21-0, Clozapine 85650-52-8, Mirtazapine 106266-06-2,
 Risperidone
 111974-69-7 122539-86-1, Olanzapine
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological
 activity); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)
 (as antipsychotic or antidepressant; new psychiatric drug
 formulation
 with an antipsychotic or antidepressant and an histamine H3
 receptor
 antagonist for prevention of psychotropic adverse effects)

L9 89 S L4 AND HISTAMINE
 L10 15 S L9 AND (H3)
 L11 4 S L10 AND (PY<=2003 OR AY<=2003 OR PRY<=2003)
 L12 3 S L11 NOT L5
 L13 275 S L4 AND BODY WEIGHT/IT
 L14 49 S L13 AND (PY<=2003 OR AY<=2003 OR PRY<=2003)
 L15 48 S L14 NOT L5
 L16 1085 S HISTAMINE H3 RECEPTORS/IT
 L17 33 S L16 AND BODY WEIGHT/IT
 L18 15 S L17 AND (ANTIDEPRESSANT? OR ANTIPSYCHOTIC? OR
 PSYCHOTROPIC? O
 L19 14 S L18 NOT L5
 L20 11 S L17 AND ANTIDEPRESSANTS/IT
 L21 10 S L20 NOT L5
 L22 12 S L3 AND HISTAMINE H3 RECEPTORS/IT
 L23 0 S L12 AND BODY WEIGHT/IT
 L24 1 S L22 AND BODY WEIGHT/IT

L24 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2010 ACS on STN
 TI New psychiatric drug formulation with an antipsychotic or
 antidepressant
 and an histamine H3 receptor antagonist for the prevention of
 psychotropic
 adverse effects

AB The invention relates to a drug formulation with an antipsychotic
 or an antidepressant, which causes adverse effects like body
 weight gain or sedation when administered, and an histamine H3
 receptor antagonist or inverse agonist. The histamine H3 receptor
 antagonist or inverse agonist should be present in the formulation
 in therapeutically effective quantities to ensure at least one of
 the three following effects on the adverse effects induced by the
 antipsychotic or the antidepressant: suppression or limitation of
 weight gain, suppression or limitation of the decrease in
 vigilance, enhancement of the pro-cognitive effect of the
 treatment.

ACCESSION NUMBER: 2005:589 HCAPLUS Full-text
 DOCUMENT NUMBER: 142:79960
 TITLE: New psychiatric drug formulation with an
 antipsychotic
 or antidepressant and an histamine H3 receptor
 antagonist for the prevention of psychotropic
 adverse
 effects
 INVENTOR(S): Schwartz, Jean Charles; Rousseau Lecomte,

Jeanne Marie
 PATENT ASSIGNEE(S): Bioprojet, Fr.
 SOURCE: Fr. Demande, 32 pp.
 CODEN: FRXXBL
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2856596	A1	20041231	FR 2003-7836	
20030627				
FR 2856596	B1	20070427		
CA 2530381	A1	20050106	CA 2004-2530381	
20040625				
WO 2005000315	A1	20050106	WO 2004-FR1628	
20040625				
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1641461	A1	20060405	EP 2004-767475	
20040625				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP 2007516160	T	20070621	JP 2006-516331	
20040625				
MX 2005013877	A	20060313	MX 2005-13877	
20051216				
US 20060210624	A1	20060921	US 2005-562396	
20051227				
PRIORITY APPLN. INFO.:			FR 2003-7836	A
20030627				
			WO 2004-FR1628	W
20040625				
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S):				

IC ICM A61K031-4453
 ICS A61K031-4164; A61P025-24; A61P025-18; A61K031-5513; A61K031-517;
 A61K031-554; A61K031-496
 CC 63-6 (Pharmaceuticals)
 IT Body weight
 (gain, as an adverse effect from antipsychotics and
 antidepressants;
 new psychiatric drug formulation with an antipsychotic or
 antidepressant and an histamine H3 receptor antagonist for
 prevention
 of psychotropic adverse effects)
 IT Histamine H3 receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (new psychiatric drug formulation with an antipsychotic or
 antidepressant and an histamine H3 receptor antagonist for
 prevention
 of psychotropic adverse effects)
 IT 288-32-4D, Imidazole, derivative 362665-56-3,
 3-(4-Chlorophenyl)propyl 3-piperidinopropyl ether
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (as histamine H3 receptor antagonist; new psychiatric drug
 formulation
 with an antipsychotic or antidepressant and an histamine H3
 receptor
 antagonist for prevention of psychotropic adverse effects)

L25 2 S L22 AND (ANTIDEPRESSANT? OR ANTIPSYCHOTIC?)
 L26 0 S L25 NOT L5
 L27 3 S L22 AND MENTAL AND BEHAVIORAL DISORDERS/IT
 L28 1 S L27 NOT L5

FILE 'REGISTRY' ENTERED AT 17:01:07 ON 25 MAR 2010
 E 362665-56-3/RN

L29 1 S E15